Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    14613986 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Condition: Melanoma Stage III or IV
Intervention: Biological: Peptide-pulsed dendritic cells
2 Completed Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients
Condition: Melanoma Stage III or IV
Intervention: Biological: autologous dendritic cell vaccine
3 Completed Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients
Condition: Melanoma
Interventions: Drug: Daclizumab;   Biological: Dendritic cells

Indicates status has not been verified in more than two years